Phanes Therapeutics Expands Dosing in Spevatamig Clinical Study for Biliary Tract Cancer Phanes Therapeutics has initiated a dose expansion phase for spevatamig in combination with chemotherapy for biliary tract cancer treatment, following toxin clearance.

Phanes Therapeutics Expands Dosing in Spevatamig Clinical Study for Biliary Tract Cancer #USA #San_Diego #Phanes_Therapeutics #Spevatamig #biliary_tract

Phanes Therapeutics Set to Showcase Innovative Cancer Treatments at AACR 2026 Phanes Therapeutics will unveil three important clinical posters at AACR 2026, focusing on their promising drug, spevatamig, for cancer treatment.

Phanes Therapeutics Set to Showcase Innovative Cancer Treatments at AACR 2026 #United_States #San_Diego #Phanes_Therapeutics #Spevatamig #AACR_2026

Exciting Phase 2 Trial Results for Spevatamig Show Promise in Treating Metastatic PDAC Phanes Therapeutics recently showcased promising Phase 2 results for spevatamig in combination with chemotherapy for metastatic PDAC patients, revealing significant efficacy and safety.

Exciting Phase 2 Trial Results for Spevatamig Show Promise in Treating Metastatic PDAC #United_States #San_Diego #Phanes_Therapeutics #PDAC #Spevatamig

Phanes Therapeutics Unveils Spevatamig Study Results at ASCO GI 2026 Phanes Therapeutics will present groundbreaking Phase 1/2 results on Spevatamig in frontline treatment of metastatic PDAC at ASCO GI 2026.

Phanes Therapeutics Unveils Spevatamig Study Results at ASCO GI 2026 #United_States #San_Francisco #Phanes_Therapeutics #PDAC #Spevatamig

Phanes Therapeutics Begins First Patient Dosing in BTC Study with Spevatamig and Chemotherapy Phanes Therapeutics has commenced dosing its first patient in a clinical study that examines spevatamig combined with chemotherapy for biliary tract carcinoma.

Phanes Therapeutics Begins First Patient Dosing in BTC Study with Spevatamig and Chemotherapy #United_States #San_Diego #Phanes_Therapeutics #Chemotherapy #Spevatamig

Phanes Therapeutics Initiates Clinical Trial for Cancer Treatment with Mavrostobart and Chemotherapy Phanes Therapeutics has begun its clinical trials for mavrostobart, an innovative cancer treatment combined with chemotherapy, marking a significant milestone.

Phanes Therapeutics Initiates Clinical Trial for Cancer Treatment with Mavrostobart and Chemotherapy #USA #San_Diego #Cancer_Treatment #Phanes_Therapeutics #Mavrostobart

Phanes Therapeutics Begins Clinical Examining of Peluntamig for Cancer Therapy Phanes Therapeutics has initiated a clinical study investigating peluntamig (PT217) combined with chemotherapy for treating SCLC and NEC, showcasing promising advancements.

Phanes Therapeutics Begins Clinical Examining of Peluntamig for Cancer Therapy #USA #San_Diego #oncology #Phanes_Therapeutics #Peluntamig

Phanes Therapeutics’ PT217 Receives FDA Fast Track Designation for NEPC Treatment Phanes Therapeutics announced that their drug PT217 has received Fast Track Designation from the FDA for neuroendocrine prostate cancer, enhancing its development prospects.

Phanes Therapeutics’ PT217 Receives FDA Fast Track Designation for NEPC Treatment #United_States #San_Diego #Phanes_Therapeutics #PT217 #FDA_Fast_Track